Potential adjunctive therapies in adolescents with type 1 diabetes mellitus

Treatments in Endocrinology

Volumn 3, Issue 6, 2004, Pages 337-343

  Jefferies, Craig A ^a   Hamilton, Jill ^a   Daneman, Denis ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN; BIGUANIDE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; MIGLITOL; PIOGLITAZONE; PIRENZEPINE; PRAMLINTIDE; RECOMBINANT SOMATOMEDIN C; ROSIGLITAZONE; TROGLITAZONE; VOGLIBOSE;

ADOLESCENT; CLINICAL TRIAL; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EDEMA; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TREATMENT; INTRAVENOUS GLUCOSE TOLERANCE TEST; LACTIC ACIDOSIS; METABOLIC REGULATION; PAIN; PATIENT SELECTION; PRIORITY JOURNAL; RETINOPATHY; REVIEW;

ADOLESCENT; DIABETES MELLITUS, TYPE 1; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 9144235676     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403060-00002     Document Type: Review

References (55)

1. Bliss M. The discovery of insulin. Toronto (ON): McClelland and Stewart Ltd, 1982
2. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 30 (14): 977-86
3. Mortensen HB, Hougaard P. Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. Diabetes Care J 1997; 20 (5): 714-20
4. Holl RW, Swift PG, Mortensen HB, et al. Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group. Eur J Pediatr 2003; 162 (1): 22-9
5. Hamilton J, Daneman D. Deteriorating diabetes control during adolescence: physiological or psychosocial? J Pediatr Endocrinol Metab 2002; 15 (2): 115-26
6. Amiel S, Sherwin R, Simonson D, et al. Impaired insulin action in puberty: a contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986; 315 (4): 215-9
7. Moran A, Jacobs DRJ, Steinberger J, et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes 1999; 48 (10): 2039-44
8. Arslanian SA, Heil BV, Becker DJ, et al. Sexual dimorphism in insulin sensitivity in adolescents with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1991; 72 (4): 920-6
9. DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 1994; 125 (2): 177-88
10. Daniel JR, Hagmeyer KO. Metformin and insulin: is there a role for combination therapy? Ann Pharmacother 1997; 31 (4): 474-80
11. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108 (8): 1167-74
12. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51 (7): 2074-81
13. Ferguson AW, de la Harpe PL, Farquhar JW. Dimethyldiguanide in the treatment of diabetic children. Lancet 1961 Jun 24; I: 1367-9
14. Janssen M, Rillaerts E, De Leeuw I. Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). Biomed Pharmacother 1991; 45 (8): 363-7
15. Meyer L, Guerci B. Metformin and insulin in type 1 diabetes: the first step. Diabetes Care 2003; 26 (5): 1655-6
16. Meyer L, Bohme P, Delbachian I, et al. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 2002; 25 (12): 2153-8
17. Hamilton J, Cummings E, Zdravkovic V, et al. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003; 26 (1): 138-43
18. Sarnblad B, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 2003; 149 (4): 323-9
19. Lacigova S, Rusavy Z, Jankovec Z, et al. Metformin in the treatment of type 1 diabetics: a placebo controlled study. Cas Lek Cesk 2001 May 24; 140 (10): 302-6
20. Gomez R, Mokhashi MH, Rao J, et al. Metformin adjunctive therapy with insulin improves glycemic control in patients with type 1 diabetes mellitus: a pilot study. J Pediatr Endocrinol Metab 2002; 15 (8): 1147-51
21. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107 (4): E55
22. Loverro G, Lorusso F, De Pergola G, et al. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Gynecol Endocrinol 2002; 16 (3): 217-24
23. Kay JP, Alemzadeh R, LangJey G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50 (12): 1457-61
24. Glueck CJ, Wang P, Fontaine R, et al. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001; 29 (3): 160-9
25. Lalau J-D, Race J-M. Metformin and lactic acidosis in diabetic humans. Diabetes Obes Metab 2000; 2: 131-7
26. Faichney JD, Tate PW. Metformin in type 1 diabetes [letter]. Diabetes Care 2003; 26 (5): 1655
27. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18 Suppl. 2: S10-5
28. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001; 7 (3): 162-9
29. Hanefeld M, Koehler C, Schaper F. et al. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999; 144 (1): 229-35
30. Kawamori R. Asymptomatic hyperglycaemia and early atherosclerotic changes. Diabetes Res Clin Pract 1998; 40 Suppl.: S35-42
31. Lecavalier L, Hamet P, Chiasson JL. The effects of sucrose meal on insulin requirement in IDDM and its modulation by acarbose. Diabetes Metab 1986; 12 (3): 156-61
32. Dimitriadis G, Karaiskos C, Raptis S. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus. Horm Metab Res 1986; 18 (4): 253-5
33. Sels JP, Verdonk HE, Wolffenbuttel BH. Effects of acarbose (Glucobay) in persons with type 1 diabetes: a multicentre study. Diabetes Res Clin Pract 1998; 41 (2): 139-45
34. Riccardi G, Giacco R, Parillo M, et al. Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med 1999: 16 (3): 228-32
35. Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type I diabetes. Diabet Care 1997; 20 (3): 248-53
36. Sels JP, Kingma PJ, Wolffenbuttel BH, et al. Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus. Neth J Med 1994; 44 (6): 198-201
37. Edelman SV, Weyer MD. Unresolved challenges with insulin therapy in type I and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther 2002; 4 (2): 175-89
38. Christopoulos G, Perry KJ, Morfis M, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 1999; 1 (1): 235-42
39. Nyholm B, Orskov L, Hove KY, et al. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type I diabetes mellitus. Metabolism 1999; 48 (7): 935-41
40. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type I diabetes. Diabetes Care 2002; 3 (1): 35-6
41. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002; 4 (1): 51-61
42. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor 1 in healthy adults. N Engl J Med 1987; 317 (3): 137-40
43. Acerini CL, Patton CM, Savage MO, et al. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997; 350 (9086): 1199-204
44. Carroll PV, Christ ER, Umpleby AM, et al. IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp. Diabetes 2000; 49 (5): 789-96
45. Thrailkill KM, Quattrin T, Baker L, et al. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes: RhIGF-I in IDDM Study Group. Diabetes Care 1999; 22 (4): 585-92
46. Flyvbjerg A. Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes. Kidney Int Suppl 1997; 60: S12-9
47. Hyer SL, Sharp PS, Brooks RA, et al. Serum IGF-1 concentration in diabetic retinopathy. Diabet Med 1988; 5 (4): 356-60
48. Krassowski J, Rogala H, Jeske W, et al. Inhibition of growth hormone (GH) response to GHRH in diabetes mellitus type 1 after blockade of the cholinergic system with pirenzepine. Pol Arch Med Wewn 1992; 88 (1): 25-9
49. Krassowski J, Szulc P, Makowska A, et al. Short term pirenzepine treatment is ineffective in suppressing 24-h growth hormone secretion in type 1 diabetes mellitus. Diabetes Res Clin Pract 1993; 19 (3): 211-6
50. Martina V, Maccario M, Tagliabue M, et al. Chronic treatment with pirenzepine decreases growth hormone secretion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989; 68 (2): 392-6
51. Halldin MU, Brismar K, Tuvemo T, et al. Insulin sensitivity and lipolysis in adolescent girls with poorly controlled type 1 diabetes: effect of anticholinergic treatment. Clin Endocrinol 2002; 57 (6): 735-43
52. Baron AD, Kim D, Weyer C. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord 2002; 2 (1): 63-82
53. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45 (2): 195-202
54. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002 Mar 9; 359 (9309): 824-30
55. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004 Jun; 27 (6): 1335-42